Opus Genetics, Inc.
IRD
Rank in Stocks
#14027
Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on... Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on ophthalmology. The company is dedicated to discovering and commercializing innovative therapies to address significant unmet medical needs in patients suffering from refractive and retinal eye disorders. Its portfolio includes Phentolamine Ophthalmic Solution, currently used to reverse pharmacologically induced mydriasis (pupil dilation). This solution is also advancing through Phase III clinical trials for the treatment of presbyopia and impaired vision in dim light or at night. A leading candidate in its retinal pipeline is APX3330, a small-molecule inhibitor targeting the reduction oxidation effector factor-1 protein. APX3330 has successfully completed Phase II clinical trials for diabetic retinopathy. Furthermore, Opus Genetics is developing APX2009 and APX2014, two preclinical product candidates also aimed at various retinal indications. Originally founded in 2018 as Ocuphire Pharma, Inc., the company maintains its headquarters in Farmington Hills, Michigan.
Share Price
$4.20
Last synced: 2026-11-09
Market Cap
$349.42M
Change (1 day)
0.48%
Change (1 year)
113.20%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Opus Genetics, Inc. (IRD)
Category
Healthcare
Operating Margin for Opus Genetics, Inc. (IRD)
Operating Margin as of November 2026 TTM: -513.47%
According to Opus Genetics, Inc.'s latest financial reports, its current operating margin (TTM) is -513.47%. At the end of 2025 the company had an operating margin of -271.90%.
Operating Margin history for Opus Genetics, Inc. from 2019 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -513.47% | 88.85% |
| 2025 | -271.90% | -51.85% |
| 2024 | -564.72% | 918.43% |
| 2023 | -55.45% | -221.23% |
| 2022 | 45.74% | -101.19% |
| 2021 | -3,854.84% | 0.00% |
| 2020 | 0.00% | 0.00% |
| 2019 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.08% |
US
|
|
| -149.01% | -99.71% |
US
|
|
| 25.57% | -100.05% |
AU
|
|
| 31.23% | -100.06% |
BE
|
|
| 29.35% | -100.06% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Opus Genetics, Inc.'s operating margin
What is Opus Genetics, Inc.'s operating margin?
Opus Genetics, Inc.'s operating margin is -513.47%, as of Nov 2026.
What was Opus Genetics, Inc.'s operating margin in 2025?
In 2025, Opus Genetics, Inc.'s operating margin was -271.90%, compared with -564.72% in 2024.
How has Opus Genetics, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Opus Genetics, Inc.'s operating margin was highest in 2022 (45.74%) and lowest in 2021 (-3,854.84%).
How does Opus Genetics, Inc.'s operating margin compare with similar companies?
Opus Genetics, Inc.'s operating margin (-513.47%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.